-+ 0.00%
-+ 0.00%
-+ 0.00%

There May Be Reason For Hope In Harmony Biosciences Holdings' (NASDAQ:HRMY) Disappointing Earnings

Simply Wall St·11/16/2026 10:08:11
Listen to the news

Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) earnings announcement last week didn't impress shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income statement.

earnings-and-revenue-history
NasdaqGM:HRMY Earnings and Revenue History November 16th 2026

Zooming In On Harmony Biosciences Holdings' Earnings

In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. The ratio shows us how much a company's profit exceeds its FCF.

As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. While having an accrual ratio above zero is of little concern, we do think it's worth noting when a company has a relatively high accrual ratio. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking.

Harmony Biosciences Holdings has an accrual ratio of -0.24 for the year to September 2026. Therefore, its statutory earnings were very significantly less than its free cashflow. To wit, it produced free cash flow of US$272m during the period, dwarfing its reported profit of US$178.6m. Harmony Biosciences Holdings' free cash flow actually declined over the last year, which is disappointing, like non-biodegradable balloons.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Harmony Biosciences Holdings' Profit Performance

As we discussed above, Harmony Biosciences Holdings' accrual ratio indicates strong conversion of profit to free cash flow, which is a positive for the company. Because of this, we think Harmony Biosciences Holdings' underlying earnings potential is as good as, or possibly even better, than the statutory profit makes it seem! And the EPS is up 22% annually, over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. While it's really important to consider how well a company's statutory earnings represent its true earnings power, it's also worth taking a look at what analysts are forecasting for the future. Luckily, you can check out what analysts are forecasting by clicking here.

This note has only looked at a single factor that sheds light on the nature of Harmony Biosciences Holdings' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.